ChronoScale (CHRN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Nov, 2026Opening remarks and agenda
Meeting called to order; voting limited to proposals in the proxy statement.
Record date set for September 10, 2026; meeting notice and proxy materials distributed September 25 to stockholders of record.
Two-thirds of voting power was present, establishing a quorum; online voting remained open through poll close.
Board and executive committee updates
All seven nominees—Wes Cummins, Ying Cenly Chen, Richard Nottenburg, Ella Benson, Douglas Miller, William Clancy, and Andrew Schaap—were elected through the next annual meeting.
Overview of voting outcomes
Stockholders ratified CBIZ CPAs P.C. as independent registered public accounting firm for FY2027.
Advisory proposal to approve named executive officer compensation passed.
Restricted stock awards to non-employee directors under the 2026 Omnibus Equity Incentive Plan were ratified.
Stockholders approved adjournment if needed in connection with insufficient votes on the proposals.
Preliminary results remain subject to final certification; final results to be filed on Form 8-K within four business days.
Latest events from ChronoScale
- Seven directors remain on the ballot; Davis and Jones receive disposition-related separation benefits.CHRN
Proxy filing - Revenue rose 148% as major AI deployments target $1B annualized run-rate.CHRN
Q3 2026 - A $500 million shelf backs cloud-focused growth and a conditional ~50 MW AI deployment plan.CHRN
Registration filing - Record Q4 revenue, improved margins, and narrowed net loss highlight strong operational progress.CHRN
Q4 2024 - Revenue fell 10% year-over-year, margins improved, but liquidity risks and funding needs remain.CHRN
Q1 2025 - Q2 revenue up 5%, margins improved, but going concern risk remains without new funding.CHRN
Q2 2024 - Q3 revenue dropped 10% YoY, net loss narrowed, and CMS reimbursement was achieved.CHRN
Q3 2024 - Q2 2025 revenue dropped 58% to $2.1M as Enterprise Health sales lagged, but Personal Health surged.CHRN
Q2 2025 - Q3 2025 revenue rose 2% YoY, gross margin hit 60.3%, and liquidity risks persist.CHRN
Q3 2025